All studies
AuthorisedHuman Pharmacology (Phase I)- First administration to humansInterventional

A Study of RO7821657 in Participants with Solid Tumors

This study is testing an experimental drug called RO7821657 in adults with advanced or metastatic solid tumours. A solid tumour is a cancer that forms a physical lump, such as in the lungs, bowel, or breast. 'Advanced' or 'metastatic' means the cancer has grown deeply into nearby tissues or spread to other parts of the body. Because this is a Phase 1 'first-in-human' study, researchers are giving this drug to people for the first time. The main goal is not to test how well it cures cancer yet, but to make sure it is safe. Doctors want to find out how the body processes the drug, what side effects it might cause, and what the safest, most effective dose should be for future studies. Participants will be monitored very closely by specialist medical teams throughout the trial.

At a glance

Status
Authorised
Phase
Human Pharmacology (Phase I)- First administration to humans
Sponsor
F. Hoffmann-La Roche AG
Enrolment target
218
Start
27 Oct 2026

What is this study about?

This clinical trial is designed to investigate a new investigational medicine known as RO7821657. It is open to adults diagnosed with advanced or metastatic solid tumours. Solid tumours are cancers that grow in organs or tissues, forming a mass or lump, as opposed to blood cancers like leukaemia. When tumours are advanced or metastatic, they have either grown too large to be completely removed by surgery or have spread to other areas of the body.

For many people living with advanced cancer, standard NHS treatments such as chemotherapy, radiotherapy, or immunotherapy may have stopped working or may no longer be suitable. Clinical trials like this explore new ways to fight cancer cells. However, because RO7821657 has never been given to humans before, researchers must start with very small, carefully controlled steps to learn how it behaves in the human body.

This trial is a Phase 1 study, focusing primarily on safety. The research team will watch closely to see how the drug is absorbed, broken down, and removed by the body. They will also look for any side effects and gradually adjust the dose given to different groups of patients to establish the safest amount to use. The findings from this study will help determine whether RO7821657 can move forward into larger trials that test how well it treats the cancer.

Key takeaways

  • Testing a new drug called RO7821657 for adults with advanced or spreading solid tumours.
  • This is a Phase 1 study, meaning the drug is being tested in humans for the first time.
  • The primary goal is to find a safe dose and learn about potential side effects.
  • Participants will be monitored very closely with frequent hospital visits and tests.
  • Taking part is completely voluntary and will not affect your right to standard NHS care.

Who may be eligible?

This trial is open to adults aged 18 and older who have been diagnosed with an advanced or metastatic solid tumour. Generally, this means participants will have already tried the standard treatments available for their type of cancer, or their doctor has decided that standard treatments are no longer working or appropriate.

To join, participants usually need to be well enough to carry out everyday activities, such as walking and looking after themselves. Doctors will also check that vital organs, including the heart, liver, and kidneys, are working well enough to handle a new medication safely.

People might not be able to take part if they have certain serious medical conditions, active infections, or have had recent cancer treatments that could interfere with the study. Pregnant or breastfeeding individuals are also excluded to protect their health and the baby. A complete medical review by the study team will confirm whether the trial is a safe option for each person.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with an advanced or metastatic solid tumour.
  3. Standard cancer treatments have stopped working, or there are no suitable options left for me.
  4. I feel well enough to manage daily self-care and attend frequent hospital appointments.
  5. I am willing to undergo regular blood tests, scans, and health monitoring.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves regular visits to a specialist hospital clinic. Before starting, you will undergo tests such as blood samples, heart checks (ECGs), and imaging scans (like CT or MRI scans) to confirm the trial is right for you. If you join, you will be given the study drug, RO7821657, under the close supervision of the medical team. Throughout the study, you will have frequent check-ups and blood tests so doctors can monitor your health and watch for side effects. You will also have follow-up scans to see how your tumour responds. The total length of time you take part will depend on how your body handles the medicine and whether your cancer remains stable, but you can expect the trial to involve several months of regular hospital appointments.

Potential risks and benefits

Because this is a Phase 1 trial, there is no guarantee that the study medicine will shrink your tumour or improve your condition. However, some patients may experience a positive response, and your participation will provide vital information that could help future cancer patients. As this drug has not been given to humans before, there is a risk of unexpected side effects, which could range from mild symptoms like tiredness or nausea to more severe reactions. Your medical team will monitor you very closely to manage any issues quickly. Taking part is entirely your choice, and you are free to leave the trial at any point without it affecting your standard NHS care.

Locations (3)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    France
  • —
    Unverified
    Denmark
  • —
    Unverified
    Spain

Common questions

What does 'first-in-human' mean?

It means this is the very first time the experimental drug is being given to people. Previous testing was done in laboratory settings to check its basic safety before human testing could be approved.

Will I be given a dummy drug (placebo)?

Phase 1 cancer trials typically do not use placebos. All participants usually receive the active study medicine, often starting at low doses to ensure safety.

Will taking part cost me anything?

No, the trial drug and trial-related tests are provided free of charge. In many cases, trial sponsors can help cover reasonable travel expenses to and from the hospital.

Can I leave the trial if I change my mind?

Yes. Joining a clinical trial is completely voluntary. You have the right to withdraw at any time, for any reason, and your regular medical team will continue to look after you.

How is the trial drug given?

The exact method depends on the design of the drug, but it is typically given either as tablets to swallow or through a drip (infusion) into a vein at the clinic.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.